A revolutionary surgery that involves drilling a hole in the skull and injecting cells could repair some devastating effects of multiple sclerosis.
This month a UCLA researcher begins a widespread clinical trial of the female sex hormone estriol, produced during pregnancy, which she’s shown sharply reduces the symptoms of multiple sclerosis.
Patients given daclizumab every two weeks had a significantly reduced lesions at week 24 compared with those in the placebo group.
The TERMS (Tovaxin for Early Relapsing Multiple Sclerosis) study is testing Tovaxin, an autologous T-Cell vaccination in patients with Clinically Isolated Syndrome or Relapsing-Remitting Multiple Sclerosis
Merck Serono announced today that it has begun the ONWARD (Oral Cladribine Added ON To Rebif New Formulation in Patients With Active Relapsing Disease) Phase II study.
Merck Serono announced today that patient enrollment has been completed in the CLARITY (CLAdRIbine Tablets Treating MS OrallY) study, a Phase III pivotal clinical trial evaluating the efficacy and safety
Created especially for the public, SearchClinicalTrials.org allows you to search multiple websites for clinical trial listings, results, and publications at one time. Search by Disease or Condition, Location, Sponsor, Age, Phase, and much more.
The Immune Response Corporation has launched a phase II trial to assess the potential of NeuroVax to treat patients with multiple sclerosis.
he Betaseron® Pregnancy Registry is designed to determine whether there is an increased risk or a pattern of birth defects in the offspring of women exposed to Betaseron® at conception and during pregnancy compared to rates from women in the general US
The AVONEX® Pregnancy Exposure Registry is designed to monitor pregnant subjects and fetuses inadvertently exposed to AVONEX® and to detect any potential increase in the risk of major birth defects.
The developmental oral therapy FTY720 (fingolimod) has demonstrated sustained benefits over two years in patients suffering from relapsing multiple sclerosis (MS), indicating that it could provide an important new option for treating this disabling neurol
The study of 104 patients showed a statistically significant reduction in the total number of gadolinium enhancing T1 lesions observed on serial MRI scans of the brain at weeks 12, 16, 20 and 24 in the Rituxan-treated group compared to placebo
In this proof-of-concept study, fingolimod reduced the number of lesions detected on MRI and clinical disease activity in patients with multiple sclerosis. Evaluation in larger, longer-term studies is warranted.
Data analyzed after two years showed a 75 percent reduction in the risk of relapse for patients taking Campath compared to patients treated with Rebif, Genzyme says.
The multiple sclerosis program captured in the agreement has already completed a 24 week open label Phase IIa clinical study seeking improvement in walking distance and Kurtzke Expanded Disability Status Scale (EDSS) efficacy endpoints in chronic progress
